About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...

I Asked 3 Food Experts To Name the Best Peanut Butter—They All Said the Same Brand ...

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...